Investigational Drug Details
| Drug ID: | D120 |
| Drug Name: | Methocarbamol |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00423 |
| DrugBank Description: | Methocarbamol was developed in the early 1950s as a treatment for muscle spasticity and the associated pain.[A178441,A178450] It is a guaiacol glyceryl ether.[A178450] Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.[Label,L6268] In Canada, methocarbamol can be sold as an over the counter oral medicine at a lower dose that may be combined with [acetaminophen] or [ibuprofen].[L6295] A combination product with [acetylsalicylic acid] and [codeine] is available in Canada by prescription.[L6295] Methocarbamol was FDA approved on 16 July 1957.[L6265] |
| PubChem ID: | 4107 |
| CasNo: | 532-03-6 |
| Repositioning for NAFLD: | Yes |
| SMILES: | COC1=C(OCC(O)COC(N)=O)C=CC=C1 |
| Structure: |
|
| InChiKey: | GNXFOGHNGIVQEH-UHFFFAOYSA-N |
| Molecular Weight: | 241.2405 |
| DrugBank Targets: | Carbonic anhydrase 1 |
| DrugBank MoA: | The mechanism of action of methocarbamol is thought to be dependant on its central nervous system depressant activity.[A31312] This action may be mediated through blocking spinal polysynaptic reflexes, decreasing nerve transmission in spinal and supraspinal polysynaptic pathways, and prolonging the refractory period of muscle cells.[A178426,A178411] Methocarbamol has been found to have no effect on contraction of muscle fibres, motor end plates, or nerve fibres.[L6268] |
| DrugBank Pharmacology: | Methacarbamol is a skeletal muscle relaxant with an unknown mechanism of action.[A178426] Methacarbamol has been shown to block spinal polysynaptic reflexes, decrease nerve transmission in spinal and supraspinal polysynaptic pathways, and prolong the refractory period of muscle cells.[A178426,A178411] Methocarbamol does not act as a local anesthetic upon injection.[A178411] In animal studies, methocarbamol also prevents convulsions after electric shock.[A178426] |
| DrugBank Indication: | Methocarbamol tablets and intramuscular injections are indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.[Label,L6268] Oral methocarbamol in America may be given up to 1500mg 4 times daily for 2-3 days.[A31312] In Canada, methocarbamol containing oral formulations are sold over the counter for pain associated with muscle spasm.[L6295] However, if these combination formulations include codeine, they are prescription only.[L6295] |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T02 | Alpha-2a adrenergic receptor | ADRA2A | Target is a single protein chain | P08913 | ADRA2A_HUMAN | Details | |
| T03 | Angiotensin-converting enzyme | ACE | INHIBITOR | Target is a single protein chain | P12821 | ACE_HUMAN | Details |
| T47 | Sialin | SLC17A5 | Target is a single protein chain | Q9NRA2 | SLC17A5_HUMAN | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|